According to FDA prescribing information, nausea affects approximately 44% of patients on Wegovy (weight management dose), while vomiting, diarrhea, constipation, and abdominal pain are also common, particularly during dose escalation
Talk to your doctor first if you have a history of: Pancreatitis Gallbladder disease Kidney problems Eating disorders Severe gastrointestinal disease Depression or thoughts of self-harm The pill may also not be the right practical fit if: Your mornings are rushed or unpredictable, or if a strict daily empty-stomach routine is hard to maintain
Your specific fluid and electrolyte needs may vary based on your health conditions, activity level, and other medications
Tirzepatide, the active drug behind it, acts on the same receptors as semaglutide
In the SUSTAIN-7 trial , individuals taking 1 mg of semaglutide lost an average of 4.6 kg (10.1 lbs) over 40 weeks compared to 1.9 kg (4.2 lbs) for those on dulaglutide 1.5 mg